Therapeutic Response

KRAS p.G12C status confers therapeutic sensitivity to Adagrasib in patients with Non-Small Cell Lung Cancer.

Statements

Source and description

Krazati (adagrasib) [package insert]. FDA. The U.S. Food and Drug Administration granted accelerated approval to adagrasib for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer, as determined by an FDA approved test, who have received at least one prior systemic therapy. The product label notes that this indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR), and that continued approval for this indication may be contingent upon verification and description of a clinical benefit in a confirmatory trial(s).